

What is claimed is:

6. (Twice Amended) A method of treating or preventing thrombosis in [an individual in need thereof] a subject diagnosed as suffering from or at risk of thrombosis comprising administering a therapeutically effective amount of a tumor necrosis factor antagonist to the [individual] subject.
8. (Twice Amended) [A] The method of claim 6, wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or antigen-binding fragment thereof.
9. (Thrice Amended) [A] The method of claim 8, wherein the antibody is selected from the group consisting of[:] a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.
10. (Thrice Amended) [A] The method of claim 8, wherein the antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .
12. (Twice Amended) [A] The method of claim 8, wherein the antibody is a chimeric antibody, [wherein] said chimeric antibody [comprises] comprising (a) a non-human variable region specific for TNF or an antigen-binding portion thereof and (b) a human constant region.
13. (Thrice Amended) [A] The method of claim 12, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .

14. (Twice Amended) [A] The method of claim 12, wherein the chimeric antibody competitively inhibits binding of TNF α to monoclonal antibody cA2.
15. (Twice Amended) [A] The method of claim 14, wherein the chimeric antibody is monoclonal antibody cA2.
29. (Twice Amended) A method of decreasing plasma fibrinogen in [an individual] a subject diagnosed as suffering from or at risk of thrombosis comprising administering a therapeutically effective amount of a tumor necrosis factor antagonist to the [individual] subject.
30. (Twice Amended) [A] The method of claim 29, wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or antigen-binding fragment thereof.
31. (Thrice Amended) [A] The method of claim 30, wherein the antibody is selected from the group consisting of[:] a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.
32. (Thrice Amended) [A] The method of claim 30, wherein the antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .
34. (Twice Amended) [A] The method of claim 30, wherein the antibody is a chimeric antibody, [wherein] said chimeric antibody [comprises] comprising (a) a non-human variable region specific for TNF or an antigen-binding portion thereof

and (b) a human constant region.

35. (Thrice Amended) [A] The method of claim 34, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .
36. (Twice Amended) [A] The method of claim 34, wherein the chimeric antibody competitively inhibits binding of TNF α to monoclonal antibody cA2.
37. (Twice Amended) [A] The method of claim 36, wherein the chimeric antibody is monoclonal antibody cA2.